On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
WednesdayDec 14, 2016 1:58 pm

NetworkNewsBreaks – Vericel (NASDAQ: VCEL) Receives FDA Approval for MACI®; Shares Soar

Shares of Vericel Corp. (NASDAQ: VCEL) are up more than 60% mid-day after the company broke news of the approval of MACI® (autologous cultured chondrocytes on porcine collagen membrane) by the U.S. Food and Drug Administration (FDA) for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. "We believe that the introduction of MACI, along with investments to expand our commercial organization…

Continue Reading

TuesdayDec 13, 2016 3:17 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 13, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: IDDR: 135.45% – News: Contracted by NRECA to provide its IDDriven 2.0 Identity Software CBLY 63.33%– News: American Fiber Optics Group subsidiary secures financing for $34M manufacturing facility QFOR 56.72 % – News: Moving on momentum from recent CEO, COO appointments VMRI: 48.47% – News: Orders five Transition BASE Systems from ALTI UAS EWLL 39.13% – News: CEO was interviewed on ABC Channel 7 News in Los Angeles ENRT 33.74% – News: Initiates bench…

Continue Reading

TuesdayDec 13, 2016 3:01 pm

NetworkNewsBreaks – Revance Therapeutics, Inc. (RVNC) Reports Positive Preliminary from Phase 2 Cervical Dystonia Trial

Shares of Revance Therapeutics (NASDAQ: RVNC) are ticking higher after the biotech company reported positive interim results from its U.S. phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults, a movement disorder of the neck. Final results are expected in the first half of 2017. “ … I am particularly encouraged that in this trial RT002 exhibited a safety profile at least as good as currently marketed neurotoxins. Furthermore, with a sustained median duration of at least 24 weeks, there is a possibility that patients will require injections only two times…

Continue Reading

TuesdayDec 13, 2016 2:51 pm

NetworkNewsBreaks – Organovo (ONVO) Presenting 3D Bioprinted Human Liver Tissue Data at TERMIS-Americas Meeting

Organovo Holdings, Inc. (NASDAQ: ONVO) is presenting the first data showing survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into animal models at the ongoing TERMIS-Americas Meeting in San Diego. Organovo intends to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its therapeutic liver tissue in three to five years. “Our preclinical data show rapid vascularization and tissue engraftment, and evidence of function and durability of our 3D bioprinted human liver tissue over several weeks.  Most importantly, we see evidence of stable production of key human liver…

Continue Reading

TuesdayDec 13, 2016 2:45 pm

NetworkNewsBreaks – Soligenix, Inc. (SNGX) Prices $5,277,000 Public Offering, Debuts on Nasdaq

Soligenix (NASDAQ: SNGX, SNGXW) shares are 34% lower on its first day of uplisting to the Nasdaq Capital Market. The late-stage biopharmaceutical company this morning priced an underwritten public offering of 1,670,000 shares of its common stock and warrants to purchase up to an aggregate of 2,087,500 shares of its common stock at a combined offering price of $3.16 – for gross proceeds of approximately $5,277,200. The warrants will have an initial per share exercise price of $3.95, subject to customary adjustment in connection with stock splits, stock dividends, reclassifications, combinations and other similar events; are exercisable immediately; and will…

Continue Reading

TuesdayDec 13, 2016 2:44 pm

NetworkNewsBreaks – Achaogen, Inc. (AKAO) Proposes Common Stock Public Offering, Proceeds to Advance Plazomicin

Achaogen (NASDAQ: AKAO) has initiated an underwritten public offering of up to 5,750,000 shares of its common stock, all of which are offered by the company. Additionally, Achaogen expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 862,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The company said it intends to use the net proceeds to fund the ongoing development and preparation for potential commercialization of its lead candidate plazomicin, for which the company yesterday announced positive results in phase 3 cUTI and CRE clinical…

Continue Reading

TuesdayDec 13, 2016 2:42 pm

NetworkNewsBreaks – Cemtrex, Inc. (CETX) Schedules Upcoming Subscription Rights Offering; Shares Higher

Cemtrex (NASDAQ: CETX) this morning said its board of directors has approved a non-transferable subscription rights offering with proceeds allocated toward new product development and to supplement its acquisition growth plan. The offering will allow Cemtrex’s stockholders of record (as of 4 p.m. ET Dec. 20) to purchase units, each consisting of one share of series 1 preferred stock, paying cumulative dividends at the rate of 10% of the purchase price per year, and two five-year series 1 warrants, upon the exercise of subscription rights at $10 per unit. Cemtrex intends to offer up to 1.5 million units, giving stockholders the opportunity…

Continue Reading

TuesdayDec 13, 2016 2:08 pm

NetworkNewsBreaks – Neovasc, Inc. (NVCN), Boston Scientific Corp. (BSX) Close $75M Acquisition Deal; Shares of Both Higher

Neovasc (NASDAQ: NVCN) and Boston Scientific (NYSE: BSX) this morning reported the close of their previously announced $75 million agreement in which Boston Scientific has acquired Neovasc's advanced biologic tissue capabilities and certain manufacturing assets, as well as 11,817,000 common shares at a price of $0.60 each ($7.0 million) for a 15% equity interest in Neovasc. Per the agreement, Neovasc has been granted a license to the purchased assets and access to the facilities in order to continue its assembly activities for its remaining tissue and valve customers. Neovasc said it intends to use the proceeds of these transactions toward…

Continue Reading

TuesdayDec 13, 2016 2:06 pm

NetworkNewsBreaks – MJP International (MJPI) Takes Aim at “Burgeoning” Texas Market with New Distribution Agreement

Shares of MJP International (OTC: MJPI) are climbing in morning trade after the green products and services company announced its distribution agreement with Texas-based O.C Construction. Per the agreement, O.C Construction will have the exclusive rights to sell and distribute MJP’s products – including different types of wind turbine and solar panels - in parts of Texas. "Over $372 million dollars was invested on solar installations in Texas in 2015. Installed solar capacity in Texas has grown by 65% over the last year. We believe that there is great potential in the Texas market for growth and we will strive…

Continue Reading

TuesdayDec 13, 2016 2:04 pm

NetworkNewsBreaks – Moxian (MOXC) Marketing Solutions Amp-up O2O Commerce

The Online-to-Offline (O2O) market is increasingly desirable to merchants in many industries. Drawing potential customers from online browsing and into a physical store, however, takes strategy. Moxian, Inc. (NASDAQ: MOXC) has created an O2O platform to improve the consumer to merchant connection, enabling businesses to better market and advertise online and potentially attract them to an in-store purchase. “Moxian’s O2O platform targets small- and medium-sized enterprises, including traditional brick-and-mortar vendors, being designed to help them connect with prospects and customers at a deeper level. By integrating social media features, entertainment and gamification, and business intelligence capabilities, the Multi-Channel Social Commerce…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217